Hematopoietic stem cell genomic DNA (HSC gDNA) (HSC gDNA)

Hematopoietic stem cell (HSC) genomic DNA is the complete set of genetic material within the multipotent cells responsible for the lifelong production of all blood and immune cell lineages. It serves as the primary therapeutic target for ex vivo gene therapies and gene editing technologies designed to treat severe genetic blood disorders and certain metabolic conditions (Naldini, L., 2011, Nature Reviews Genetics). By modifying the genomic sequence of these self-renewing cells, clinicians can ensure that all subsequent progeny carry the therapeutic modification, providing a potentially curative outcome for diseases like sickle cell disease and beta-thalassemia (FDA, 2023). Therapeutic strategies include the use of lentiviral vectors for gene addition and CRISPR/Cas9 systems for precise sequence disruption or correction (Ginn, S. L., et al., 2018, Gene Therapy). Additionally, the genomic DNA of host HSCs is targeted by myeloablative conditioning agents such as busulfan, which induce DNA cross-linking to eliminate endogenous stem cells and create space for transplanted cells (Ciurea, S. O., et al., 2009, Biology of Blood and Marrow Transplantation). Despite its therapeutic promise, targeting HSC DNA involves significant challenges, including the risk of off-target mutations, insertional mutagenesis, and the potential for malignant transformation. Long-term monitoring of genomic integrity and clonal dynamics is essential for patients receiving these therapies to detect any late-onset adverse events related to genomic instability (Nature, 2021).

Other names

HSC DNAHematopoietic stem cell genomeCD34+ cell DNAHSC gDNA

Gene editing (CRISPR/Cas9-mediated double-strand breaks), gene addition (lentiviral vector-mediated integration), and DNA alkylation (non-specific chemical modification).